Angioblast Loses Contract Counterclaims Against UBS
A New York state judge on Monday dismissed stem cell research firm Angioblast Systems Inc.'s allegations that UBS Securities LLC is not entitled to $7.8 million in transaction fees related to...To view the full article, register now.
Already a subscriber? Click here to view full article